CSIMarket


Xeris Biopharma Holdings Inc   (XERS)
Other Ticker:  
 


 

Xeris Biopharma Holdings Inc

XERS's Financial Statements and Analysis



Xeris Biopharma Holdings Inc increased forth quarter of 2023 net loss per share of $-0.10 compare to net loss per share of $-0.06 recorded in the same quarter a year ago a decrease compare to $-0.09 realized in previous quarter.


forth quarter of 2023
Earnings Per Share Revenues
$ -0.1 $  44 Mill
$-0.04     $+11M     +33.93 %



Xeris Biopharma Holdings Inc 's Revenue rose by 33.93 % in forth quarter of 2023 (Dec 31 2023) year on year, to $44 million and declined by -8.13 % sequentially.


Xeris Biopharma Holdings Inc is

More on XERS's Income Statement



Xeris Biopharma Holdings Inc 's net income of $33.904 million in the forth quarter of 2023 increased by 9930.77 % from net earnings of $0.338 million achieved in IV. Quarter a year ago.

Sequentially net earnings grew by 9930.77 % from net income of $0.338 million realized in previous quarter.

More on XERS's Growth

Xeris Biopharma Holdings Inc Inventories
Inventories grew by 57.02 % to $39 million from IV. Quarter a year ago, sequentially inventories rose by 1.82 %. XERS's Cash flow In the forth quarter of 2023 company's net cash flow was $21 million


Xeris Biopharma Holdings Inc does not pay out common stock dividend.

In trailing twelve-month period Xeris Biopharma Holdings Inc payed $ -0.34 cash per share, on a free-cash flow basis .


Tangible Book value fell to $ -1.01 per share from $ -0.95.

Company issued 0.28 million shares or 0.21 % in Dec 31 2023.
Interest Coverage Ratio was 1.11. Debt Coverage Ratio was 0.13.

More on XERS's Dividends

 Market Capitalization (Millions) 284
 Shares Outstanding (Millions) 138
 Total Debt (Millions $) 191
 Revenue (TTM) (Millions $) 164
 Net Income (TTM) (Millions $) 1
 Cash Flow (TTM) (Millions $) -55
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 100




Xeris Biopharma Holdings Inc does not pay out common stock dividend.

In trailing twelve-month period Xeris Biopharma Holdings Inc had negative $ -0.34 cash flow per share, on a free-cash flow basis .


Tangible Book value fell to $ -1.01 per share from $ -0.95.

Company issued 0.28 million shares or 0.21 % in Dec 31 2023.
Interest Coverage Ratio was 1.11. Debt Coverage Ratio was 0.13.

More on XERS's Balance Sheets

 Market Capitalization (Millions) 284
 Shares Outstanding (Millions) 138
 Total Debt (Millions $) 191
 Revenue (TTM) (Millions $) 164
 Net Income (TTM) (Millions $) 1
 Cash Flow (TTM) (Millions $) -55
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 100
   


  News about Xeris Biopharma Holdings Inc Earnings

Xeris Biopharma Holdings Inc Faces Intensified Losses in Fiscal Report Ending December 31, 2023

Xeris Biopharma Holdings Inc, a major pharmaceutical preparations company, recently released its financial results for the October to December 31, 2023 time-frame. Despite a decrease in the company's earnings per share, there was a significant surge in revenue, indicating positive growth for the company.
The company reported a shortfall per share of $-0.10 during the specified time-frame, compared to a shortfall of $-0.09 in the previous reporting period. Although this represents a slight increase in loss per share, it is important to note that there was substantial revenue growth during the same period. Xeris Biopharma's revenue increased by an impressive 33.931% to $44.39 million, up from $48.32 millio...


Date modified: 2024-03-07T21:19:17+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com